Stevanato Group S.p.A. (STVN) News
Filter STVN News Items
STVN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
STVN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest STVN News From Around the Web
Below are the latest news stories about STEVANATO GROUP SPA that investors may wish to consider to help them evaluate STVN as an investment opportunity.
UTHR vs. STVN: Which Stock Is the Better Value Option?UTHR vs. STVN: Which Stock Is the Better Value Option? |
Estimating The Fair Value Of Stevanato Group S.p.A. (NYSE:STVN)Key Insights Stevanato Group's estimated fair value is US$22.49 based on 2 Stage Free Cash Flow to Equity With US$24.11... |
Stevanato Group to Present at Upcoming Investor ConferencePIOMBINO DESE, Italy, January 07, 2025--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the CJS Securities 25th Annual "New Ideas for the New Year" Investor Conference on Tuesday, January 14, 2025, at 8:00 a.m. ET. |
Wolfe starts Stevanato with Outperform on return to growthWolfe Research initiated coverage of Stevanato Group (STVN) with an Outperform rating and $28 price target The company is poised to return to double-digit revenue growth as a supplier of key enabling components and solutions to biopharma, the analyst tells investors in a research note. The firm does not expect Stevanato’s growth to inflect, but believes it “is on the verge of turning the corner.” The company’s revenue growth should return to high-single digit levels over the course of 2025 and m |
Stevanato Group assumed with an Equal Weight at Morgan StanleyMorgan Stanley analyst Tejas Savant assumed coverage of Stevanato Group (STVN) with an Equal Weight rating and a price target of $23, down from $24. Stevanato, with “market leading positions” in the biopharmaceutical injectables end market, is well-positioned to benefit in terms of both top-line and margins from a structural mix shift towards biologics and growth in GLP-1s, but vial destocking headwinds, cost under-absorption related to necessary capacity buildouts and optimization expenses are |
Earnings Troubles May Signal Larger Issues for Stevanato Group (NYSE:STVN) ShareholdersThe market rallied behind Stevanato Group S.p.A.'s ( NYSE:STVN ) stock, leading do a rise in the share price after its... |
Stevanato Group to Present at Upcoming Investor ConferencesPIOMBINO DESE, Italy, November 11, 2024--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences. |
CPRX vs. STVN: Which Stock Is the Better Value Option?CPRX vs. STVN: Which Stock Is the Better Value Option? |
Stevanato Group Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsStevanato Group ( NYSE:STVN ) Third Quarter 2024 Results Key Financial Results Revenue: €277.9m (up 2.4% from 3Q 2023... |
Stevanato Group SpA (STVN) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ChallengesStevanato Group SpA (STVN) reports modest revenue growth and strategic advancements, while addressing margin pressures and revised guidance. |